Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Soliris eculizumab: Phase III data

In the open-label, international Phase III E05-001 extension trial in 195 patients, Soliris

Read the full 130 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE